BIO-TECHNE Corp Share Price Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
02/05 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
02/05 | Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 | MT |
Sales 2024 * | 1.16B 96.59B | Sales 2025 * | 1.25B 104B | Capitalization | 12.15B 1,013B |
---|---|---|---|---|---|
Net income 2024 * | 180M 15B | Net income 2025 * | 225M 18.75B | EV / Sales 2024 * | 10.6 x |
Net Debt 2024 * | 178M 14.81B | Net cash position 2025 * | 16.78M 1.4B | EV / Sales 2025 * | 9.72 x |
P/E ratio 2024 * |
69.1
x | P/E ratio 2025 * |
55.4
x | Employees | - |
Yield 2024 * |
0.41% | Yield 2025 * |
0.41% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 30/18/30 |
James Hippel
DFI | Director of Finance/CFO | 53 | 01/14/01 |
Matthew McManus
COO | Chief Operating Officer | 55 | 08/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 01/03/01 | |
Randolph Steer
BRD | Director/Board Member | 74 | 01/90/01 |
Joseph Keegan
BRD | Director/Board Member | 71 | 26/17/26 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
-1.24% | 11.99B | |
+19.33% | 11.64B |